Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 11/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.41 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22169013 | 0.88 | KIF11 (0.40) | CACNA1HCACNA1CCACNA1BCACNA1GMAPT | |
| SCHEMBL7779818 | 0.85 | GRIN1 (0.46) | CACNA1HCACNA1CCACNA1BGPR17CACNA1G | |
| SCHEMBL23269912 | 0.83 | MAPT (0.44) | MAPTABCG2KMT2A | |
| SCHEMBL8873491 | 0.82 | GRIN1 (0.41) | CACNA1HCACNA1CCACNA1BGPR17CACNA1G | |
| SCHEMBL30211489 | 0.81 | MAPT (0.36) | MAPTABCG2KMT2A | |
| SCHEMBL24898687 | 0.81 | MAPT (0.36) | MAPTABCG2KMT2A | |
| SCHEMBL2420442 | 0.80 | GRIN1 (0.42) | EGLN1MAPTABCG2KMT2A | |
| SCHEMBL2417841 | 0.80 | RIPK1 (0.37) | EGLN1MAPTABCG2KMT2A | |
| SCHEMBL2419473 | 0.80 | ALDH1A1 (0.38) | MAPTABCG2KMT2A | |
| SCHEMBL2419588 | 0.80 | BRAF (0.35) | MAPTABCG2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042743-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | COUNCIL SCIENT IND RES (IN) | 2026-02-12 | — | — | US | disclosed |
| US-8026241-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-7582761-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090143575-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | BALAN CHENERA | 2009-06-04 | — | — | US | disclosed |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143575-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV3, TRPV2 | CACNA1H 558/4885CACNA1C 485/4885CACNA1B 458/4885 |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | CACNA1H 532/4885CACNA1C 453/4885CACNA1B 519/4885 |
| US-20260042743-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | ACE2, SARS1, NR3C2 | CACNA1H 1849/4885CACNA1C 1701/4885CACNA1B 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.